Tagged with oncology,

China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021.   Since first joining the company back in 2002, Afonso held a variety of roles IT…

Global Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being done on patient engagement and expectation management for the firm’s cutting-edge CAR-T therapies, and how a stronger patient voice can…

USA Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also explains how the work of his CAR-T team at the University of Washington School of Medicine could provide proof of…

Global PharmaBoardroom has spoken to leaders from several important global patient advocacy organisations in 2021 who shared their concerns on crucial global healthcare issues. These range from the greater levels of pharma industry investment needed in childhood cancers; the myriad of patient explanation and expectation management needed around CAR-T therapies; how…

Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.   Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…

USA Claire Saxton and Lauren Kriegel of Cancer Support Community, the largest professionally led non-profit network of cancer support worldwide, discuss how cancer patient and caregiver perspectives need to be better integrated into the treatment process. This is an especially prescient issue for next-generation cell and gene therapies such as CAR-T…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Europe The Lymphoma Coalition’s Natacha Bolaños outlines the fundamentals of the lymphoma patient experience today, the growing number of innovative new treatment options available, and the issues surrounding their integration as earlier lines of treatment.   CAR-T is not necessarily the best treatment option for everyone. There could be other second-best…

Denmark Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing innovative medicines to patients, gives her thoughts on the new Danish National Life Science Strategy, and outlines how Danish patients could have even better access to innovation.   All stakeholders…

USA Dr Sam Volchenboum outlines the progress that has been made in the paediatric oncology field in recent years and his hopes for its future. Dr Volchenboum also explains the important role that data will play in the new era of targeted and personalised therapies and the impact of the work…

Singapore AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the backdrop of a pandemic and how the Anglo-Swedish company’s quest for a COVID-19 vaccine has opened up new partnership opportunities in the region. Narayanan also touches on Singapore’s open ecosystem…